On July 18th, Gelonhui announced that its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group Co., Ltd., received the Supplemental Application Approval Notice for Pharmaceutical from the National Medical Products Administration, regarding Carbaspirol Sodium Tablets. This means that the quality and efficacy of the pharmaceutical is equivalent to that of the original drug. Jiangsu Wuzhong Pharmaceutical Development possesses related institutional branches in Suzhou, including Suzhou Pharmaceutical Factory.
Carbaspirol Sodium is a new generation of adrenaline-derived hemostatic drug that enhances microvascular resistance to injury or reduces microvascular permeability, promotes the retraction of the ends of broken capillaries, stabilizes acidic mucopolysaccharides in microvessels and surrounding tissues, and significantly shortens bleeding time. It does not affect the coagulation/fibrinolysis system and is an effective hemostatic drug for bleeding caused by microvessel injury. In clinical practice, Carbaspirol Sodium is mainly used for bleeding disorders in the urinary system, upper gastrointestinal tract, respiratory tract, and obstetrics and gynecology. Its anti-bleeding effect is particularly remarkable for urinary system bleeding, and it can also be used for bleeding caused by trauma and surgery.